Australia markets closed

Neoleukin Therapeutics, Inc. (NLTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.01-0.16 (-1.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.17
Open8.22
Bid7.85 x 2200
Ask8.03 x 1200
Day's range7.78 - 8.34
52-week range7.78 - 17.95
Volume93,536
Avg. volume176,463
Market cap339.189M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-0.74
Earnings date10 Aug 2021 - 16 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.40
  • Insider Buying: The Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) CEO, President & Director Just Bought 2.3% More Shares
    Simply Wall St.

    Insider Buying: The Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) CEO, President & Director Just Bought 2.3% More Shares

    Potential Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) shareholders may wish to note that the CEO, President...

  • Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference

    SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event. About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com. Safe Harbor / Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contacts: MediaJulie Rathbun206-769-9219jrathbun@neoleukin.com InvestorsSolebury TroutAlexandra Roy617-221-9197aroy@soleburytrout.com

  • Is Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Popular Amongst Insiders?
    Simply Wall St.

    Is Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Popular Amongst Insiders?

    A look at the shareholders of Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) can tell us which group is most powerful...